---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090183"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-08-14T20:35:17+00:00"
generated_at: "2026-08-14T20:40:58.969662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity Q2 2026: cash $26.9M, loss $3.7M; stenoparib manufacturing completed

## Summary
- Cash and restricted cash $26.9M at June 30, 2026, up from $14.7M a year ago.
- Q2 comprehensive loss $3.7M vs $4.2M; six-month loss $6.5M vs $7.2M.
- R&D expenses $1.3M (down from $2.3M); G&A $1.3M (down from $1.8M).
- Completed Phase 3-ready stenoparib API manufacturing campaign in July 2026, ahead of schedule.
- USPTO granted key patent for stenoparib DRP companion diagnostic, exclusivity to 2042.

## SEC filing metadata
- accession: 0001213900-26-090183
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-08-14T20:35:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/0001213900-26-090183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea0302157-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090183
- JSON: https://secwatch.observer/filing/0001213900-26-090183.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.